GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (NAS:ACHL) » Definitions » Inventories, Raw Materials & Components

Achilles Therapeutics (Achilles Therapeutics) Inventories, Raw Materials & Components : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Inventories, Raw Materials & Components?

Achilles Therapeutics's inventories, raw materials & components for the quarter that ended in Dec. 2023 was $0.00 Mil.


Achilles Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for Achilles Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Inventories, Raw Materials & Components Chart

Achilles Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
- - - - -

Achilles Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Achilles Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Achilles Therapeutics (Achilles Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (Achilles Therapeutics) Headlines

From GuruFocus

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

By GuruFocusNews GuruFocusNews 07-01-2022